Acceleron Pharmaceuticals (XLRN) boosted its stock price this summer following the successful readout from a pair of late-stage clinical trials in which its experimental drug significantly reduced the need for blood transfusions in patients with two different blood diseases.
But Acceleron and its partner Celgene (CELG) kept details on the magnitude of the luspatercept benefit under wraps at the time. On Thursday, the data were revealed in research abstracts released ahead of next month’s American Society of Hematology annual meeting.
From a commercial perspective, the more important trial of the drug, luspatercept, involved 229 patients with myelodysplastic syndrome (MDS) — a cancer-like disease of the bone marrow.
About the Author Reprints
I’m looking for healthy subject study